u/StockEnthuasiast

This might be one of several other factors that's supporting the rally.

Date: In 10 minutes.

Evidence: His extensive works in literature.

Here I’m sharing a very recent interesting video take just posted 2 hours ago from Dan Costin, MD. What stood out to me is that he sees personalized cancer vaccines as potentially useful across all stages of lung cancer, not just in early-stage disease, and even raises the possibility of eventually de-escalating other treatments if the data become strong enough. That is obviously forward-looking, but it shows how broad the potential could be. Let’s keep sharing useful information like this.

Unrelated to the video above, with the recent increase in negativity from some bearish posters, I think we should use our own judgment about what is worth engaging with. If a bearish post is made in good faith and genuinely challenges or balances our bullish view, we should absolutely read it and consider it.

But if it comes with rabid insults, mockery, unnecessary provocation, or repetitive spam that adds no original angle, I think the best response is simply not to engage. I’m going to make it a rule for myself that when I see that kind of poster with no apparent goodwill, I will just mute them.

I’m not muting them because they are bearish, and I’m not trying to create an echo chamber. I want bearish information. I just want it without the emotional noise. The point is not to shield our bullish view from criticism, but to prevent pointless fights from making us unnecessarily defensive about the stock and emotionally invested in proving someone else wrong.

It’s perfectly fine to like the stock. But we should still try to keep our judgment as objective as possible.

I’ve also noticed, as another user pointed out, that some bearish posters don’t really engage with the specific material being shared. A new article, video, dataset, or argument gets posted, and instead of addressing it, they simply return to the same repetitive talking points. That doesn’t add much to the discussion.

Some also seem more interested in drawing attention to themselves than to the topic at hand. I’d rather we bring the focus back to the substance. Otherwise the discussion eventually descends into noise and chaos.

Ignoring bad-faith behavior is not the same as ignoring the bearish thesis. In fact, it is precisely because I want to hear useful bearish arguments that I would rather separate the information from the hostility and personal drama.

1. Immediate catalyst: full Phase 3 melanoma data and regulatory filing

The full Phase 3 intismeran autogene melanoma data remain the most immediate catalyst.

The Bernstein analyst explicitly raised ESMO during the discussion.

What management did emphasize was the strength of what is already known:

• The trial beat Keytruda, not placebo.
• It met the primary RFS endpoint at the first interim analysis.
• It also met the secondary DMFS endpoint at the first interim analysis.
• The trial included both Stage II and Stage III disease, with Stage II generally considered harder to demonstrate incremental benefit in.
• It was an approximately 1,100-patient, rigorously controlled Phase 3 trial.

David Berman said he is "very confident that we have a strong case for approval."

Bancel also said Moderna and Merck are focused on filing the BLA as quickly as possible.

The upcoming detailed dataset should therefore help define the magnitude, consistency, subgroup behavior, and ultimately the commercial potential of INT in melanoma.

2. Management sounds increasingly confident that melanoma is only the first validation

The more interesting part of the Bernstein discussion was how management framed the implications of the Phase 3 success.

Bancel said Moderna and Merck currently have nine INT studies ongoing, but that their development plan should change now that they know INT works in Phase 3.

Before Phase 3, the mechanism was supported by earlier clinical and translational evidence.

Now Moderna has Phase 3 validation, along with mechanistic evidence that the treatment can generate de novo T cells and expand existing T-cell populations.

That appears to be increasing management's willingness to accelerate additional studies.

The key question is therefore shifting from:

"Does INT work?"

to:

"How broadly can INT work?"

3. A very important statement: management believes INT may not require a PD-1

Berman made one of the strongest statements of the conference:

"Intismeran does not need a PD-1 to be active."

He repeated it deliberately when the Bernstein analyst asked him to say it again.

This remains a hypothesis that must be demonstrated clinically, but the strategic implications are significant.

If correct, INT could potentially move into earlier-stage cancers where checkpoint inhibitors are less attractive or are not routinely used.

That is why Moderna is already studying INT in settings such as:

• Stage I lung cancer
• NMIBC with BCG
• other very early-stage disease

The long-term strategy appears to be much broader than simply adding INT to Keytruda wherever Keytruda is already used.

4. The broader INT thesis: wherever checkpoint inhibitors work, INT may add value

Berman pointed to the Phase 2 melanoma analysis showing similar efficacy in high and low tumor mutational burden groups.

His interpretation is that INT does not require extraordinarily high TMB. It needs enough suitable neoantigens to construct the personalized vaccine.

That leads management to believe that tumors such as RCC could still respond despite having lower TMB than melanoma.

Bancel summarized the broader strategy as:

1. Add INT to immuno-oncology where checkpoint inhibitors already work.
2. Move INT into earlier-stage disease, potentially even as monotherapy.
3. Combine INT with other agents through complementary mechanisms.

The melanoma result alone does not establish that INT will work across different tumor types. The upcoming non-melanoma studies are what will test that thesis.

5. RCC and bladder cancer remain critical next tests

After melanoma, renal cell carcinoma and bladder cancer should provide some of the most informative evidence on whether the platform is truly portable across tumors.

Berman indicated that RCC and bladder cancer readouts could come over roughly the next 12 months.

RCC is particularly interesting because it pushes INT into a different biological setting with lower TMB.

A positive result there would strengthen the case that the melanoma success is not limited to a highly immunogenic tumor.

6. Lung cancer continues moving forward

Moderna has three Phase 3 lung cancer trials.

Berman said screening has stopped in the leading Phase 3 adjuvant lung study involving patients without prior neoadjuvant therapy, and randomization is expected to be completed later this year.

The lung program spans multiple stages of disease, including very early-stage disease.

The most ambitious version of management's thesis is Stage I lung cancer treated with INT without requiring a checkpoint inhibitor.

That would take time to establish, but medically and commercially it could substantially expand the addressable population if successful.

7. More oncology catalysts beyond INT

INT is not the only oncology program Moderna expects to produce data from.

Several additional programs were highlighted.

Pancreatic cancer

Phase 1 pancreatic INT data are anticipated later this year.

Pancreatic cancer represents a much more difficult, low-TMB setting, so this should be viewed as exploratory rather than equivalent to the randomized melanoma, RCC, or bladder programs.

Multiplex T-cell engagers

Moderna is testing an mRNA therapy encoding three T-cell engagers in heavily pretreated multiple myeloma patients.

Berman said data should be shared later this year.

Management views this as a sentinel program. If multiplexing works clinically here, it could support expansion of the approach into additional cancers.

Shared cancer antigen therapies

Moderna is also developing off-the-shelf cancer antigen therapies rather than only individualized therapies.

Management explicitly acknowledged that these programs carry greater scientific risk than INT, but Phase 1 studies are underway.

8. Lynch syndrome could become an entirely different type of cancer vaccine opportunity

One of the more interesting longer-term programs discussed was Lynch syndrome.

Because patients with Lynch syndrome share certain recurrent frameshift neoantigens, Moderna believes it may be possible to develop an off-the-shelf vaccine intended to prevent cancer from developing in genetically high-risk individuals.

Berman sounded particularly positive about the biology and said:

"To me, it's a high probability of success."

He immediately added that the concept still needs to be proven in the clinic.

The ultimate goal is cancer interception or prevention, treating people with Lynch syndrome before cancer develops.

Importantly, Moderna owns this program 100%, unlike INT, which is partnered 50/50 with Merck.

If successful, this would move the cancer vaccine concept from treating cancer toward cancer prevention.

9. Manufacturing continues to sound much less problematic than previously feared

Bancel spent considerable time explaining why he does not view personalized INT manufacturing like CAR-T manufacturing.

INT does not require extracting and manipulating a patient's cells.

Instead, Moderna receives sequencing data and then manufactures a synthetic, cell-free mRNA product.

The manufacturing strategy is therefore primarily scale-out, adding many compact production units, rather than traditional scale-up.

Bancel also emphasized two major variables:

• reducing equipment footprint
• reducing manufacturing cycle time

His conclusion was unusually direct:

"Do I worry about manufacturing? Not a minute."

That statement does not prove that commercial-scale manufacturing will be effortless, but it shows that management believes the core technical manufacturing problem is manageable.

10. The bigger bottleneck may actually be hospitals

Interestingly, Bancel said the biggest bottleneck could be hospital workflow rather than manufacturing.

For each patient, the system needs to move tumor biopsy material, sequencing information, patient information, manufacturing orders, and treatment logistics quickly and accurately.

Moderna and Merck are therefore building teams that are going hospital by hospital to establish the necessary workflow.

They are also ranking hospitals by importance and have developed a digital platform to track the process.

This may be one of the less visible but more important aspects of commercial launch execution.

11. Moderna considers the antigen-selection process a proprietary moat

Bancel emphasized that outside sequencing partners provide Moderna with the raw healthy and tumor DNA sequence data.

The subsequent selection of the 34 mutations used in each individualized therapy is proprietary to Moderna.

He raised an interesting long-term competitive question:

How does another company demonstrate that it has reproduced an individualized product when every patient's product is different and the underlying selection methodology is proprietary?

That does not eliminate competition, but management clearly believes that INT's moat extends beyond mRNA manufacturing itself.

12. Merck economics remain straightforward: 50/50

Bancel described the Merck relationship as effectively a virtual joint venture.

The companies split costs 50/50, including:

• clinical development
• manufacturing
• capex
• opex
• commercial expenses

After expenses, remaining profits are also split 50/50.

Management deliberately avoided discussing pricing before the full Phase 3 dataset is presented.

For now, the priority is the data and getting the BLA filed quickly.

13. PA could become the proof-of-concept for an entire rare-disease platform

The pivotal propionic acidemia, or PA, readout is expected by the end of the year.

Bancel sounded highly confident based on the earlier clinical experience, particularly among patients treated at the dose selected for the pivotal study.

He said that when looking specifically at patients treated at the pivotal-study dose:

"The data is wow."

He also said he expects the pivotal data to be strong because the mechanism has already been demonstrated over several years of follow-up.

But PA matters beyond one rare disease.

Moderna views it as the first validation of repeated intravenous mRNA delivery to the liver for protein replacement.

Bancel said Moderna has published models for more than a dozen rare genetic liver diseases that could potentially use the same basic delivery and manufacturing infrastructure.

The important question is therefore not simply whether PA becomes one product.

It is whether PA validates another reusable mRNA platform.

14. Rare disease could also improve Moderna's manufacturing economics

Bancel made an interesting operational point.

The vaccine business is highly seasonal, meaning manufacturing capacity can sit underutilized for part of the year.

Rare-disease products could potentially be manufactured during those periods using some of the same fixed infrastructure.

If the rare-disease franchise grows, that could improve utilization of manufacturing assets that would otherwise be underused outside the respiratory-vaccine production cycle.

15. Management is increasingly describing Moderna as an immunology company

Bancel's broader framing was that Moderna should no longer be viewed primarily as a COVID vaccine company.

He described the company as an mRNA platform increasingly concentrated around manipulating the immune system across:

• infectious disease
• oncology
• autoimmune disease

Berman similarly described Moderna as increasingly an immunology company, with vaccines, cancer immunotherapy, and autoimmune programs all using different applications of the same underlying platform.

Whether all those programs succeed is another question, but the pipeline is becoming much more diversified than the Moderna of the pandemic period.

16. Autoimmune disease could become another major platform test

Moderna also highlighted its autoimmune pipeline, including an in vivo CAR-T program approaching the clinic and several additional autoimmune programs.

Management expects to provide more information on these programs over approximately the next 12 to 18 months.

This remains earlier-stage and therefore much less de-risked than melanoma INT or PA, but it provides another potentially large application of the platform.

17. AI is becoming part of Moderna's long-term development strategy

Bancel also spent part of his closing remarks discussing AI.

His argument is that mRNA is fundamentally an information-based medicine platform.

As biological understanding improves and AI accelerates target discovery and design, Moderna can potentially translate new biological insights into experimental medicines much faster than conventional drug-development approaches.

He used the original COVID vaccine design as the extreme example: once the viral sequence was available, the initial vaccine sequence could be designed computationally extremely quickly.

This is a long-term strategic argument rather than a near-term financial catalyst, but it helps explain why management continues to think of Moderna as a platform rather than a collection of individual products.

18. Limited new detail on the $2.6 billion convertible-note raise

Bernstein specifically asked what the recently raised $2.6 billion in convertible debt allows Moderna to do differently.

Bancel did not provide much specific detail on how the additional capital will be deployed.

Instead, he shifted the discussion toward Moderna's long-term platform opportunity, AI, scientific productivity, and the company's ability to invest behind future medicines.

The conference therefore provided limited new detail on the specific use of the additional capital.

Risks and things that still need proof

Despite the confidence throughout the discussion, management also acknowledged several important uncertainties.

• INT still needs to prove that melanoma efficacy translates into other tumor types.
• Metastatic disease may be harder because a biopsy from one lesion may not capture the heterogeneity of all lesions.
• Very low-TMB cancers such as pancreatic cancer remain exploratory.
• Off-the-shelf shared-antigen cancer vaccines carry more scientific risk than personalized INT.
• The hypothesis that INT can work without PD-1 therapy still needs clinical validation.
• Large-scale commercial execution requires hospitals to develop efficient biopsy, sequencing, and treatment workflows.
• Earlier-stage programs such as T-cell engagers, autoimmune therapies, and cancer-prevention vaccines remain far less clinically validated than melanoma INT.

Bottom line

The Bernstein discussion reinforced that the upcoming melanoma presentation and regulatory filing are only the nearest catalysts.

The broader sequence now looks something like:

Full melanoma Phase 3 data → BLA filing → PA pivotal data → additional INT readouts in RCC/bladder → early-stage pancreatic data → multiple myeloma T-cell engager data → lung Phase 3 development → broader oncology and autoimmune programs

The most reassuring points from the discussion were:

• a large randomized Phase 3 trial already meeting both RFS and DMFS at interim analysis
• management explicitly expressing confidence in the approval case
• manufacturing appearing substantially more mature than previously assumed
• nine INT studies already underway rather than waiting for melanoma before expanding
• several independent oncology programs beginning to generate their own data
• PA potentially validating a separate rare-disease platform

The key question from here is increasingly not whether Moderna can produce another product after COVID.

It is whether the Phase 3 melanoma success is the first clinical validation of a much broader therapeutic platform.

Disclaimer: This summary was prepared with the help of AI to organize and condense the conference transcript. I selected the points I found most relevant. The transcript may contain minor transcription errors, so please refer to Moderna's official materials for the full context and primary-source information.

Disclaimer: This is organized from an AI-assisted summary of the conference discussion, so there may be minor transcription errors, omissions, or misinterpretations. And for the occasional jackass who, in 2026, still sees “AI-assisted” and immediately calls a post “AI slop,” that may be more projection than anything else. Anyone with even half a brain should understand the difference between using AI as a tool and letting it do the thinking for you. In this particular case, it’s mostly a summary, but I trimmed it down and emphasized the parts that caught my attention.

1. Immediate catalyst: Phase 3 melanoma full data

Full Phase 3 melanoma data are expected at an upcoming medical meeting. ESMO was specifically raised by Morgan Stanley, although Moderna did not confirm the venue.

Key things to watch:

• Hazard ratio. The analyst suggested <0.75 would be exciting and ~0.65 ideal. Hoge called those reasonable benchmarks.
• Stage II subgroup.
• When the curves separate and whether the separation strengthens over time.
• Consistency across subgroups and versus Phase 2.

2. The next major tests: RCC and MIBC

Both renal cell carcinoma (RCC) and muscle-invasive bladder cancer (MIBC) are roughly 300-patient, randomized, event-driven Phase 2 trials and are essentially fully enrolled.

RCC may be the most scientifically important readout after melanoma. RCC has much lower tumor mutational burden than melanoma, making it a strong test of whether INT can work beyond highly immunogenic tumors.

The counterpoint is that RCC still generates potentially useful neoantigens, including indels and frameshifts, and Keytruda already works in RCC. The question is whether INT can focus the immune response further.

MIBC provides another independent randomized test of whether INT can add benefit on top of an effective checkpoint inhibitor.

3. NMIBC: important because it tests INT alone

The non-muscle-invasive bladder cancer study tests INT monotherapy, rather than INT + Keytruda.

A positive result would suggest that checkpoint inhibition may not always be required.

Hoge indicated that this Phase 2 study could also read out relatively soon.

4. Moderna/Merck built a multi-year catalyst sequence

The INT program was deliberately designed so that Moderna and Merck would not finish melanoma and only then begin testing other cancers.

The expected sequence is roughly:

Melanoma → RCC → MIBC → NMIBC → multiple lung studies → additional indications

Hoge described this as waves of clinical data roughly every six months.

So melanoma may be the beginning of a prolonged catalyst cycle rather than the end of the story.

5. Lung cancer is the major longer-term opportunity

Moderna/Merck have three randomized Phase 3 lung cancer trials plus additional Phase 2 work.

The program spans:

• adjuvant disease
• neoadjuvant disease
• Stage I
• metastatic disease
• possible monotherapy

These trials will take longer to mature, but lung cancer could become one of the largest commercial opportunities if INT works.

6. Earlier-stage disease may become the core INT strategy

Hoge repeatedly emphasized adjuvant disease, Stage I disease and minimal residual disease.

The logic is straightforward: remove the bulk of the tumor, then use INT to prime T cells against remaining microscopic disease and prevent recurrence.

INT's relatively favorable safety profile also makes earlier treatment more feasible.

7. Phase 2 melanoma gives clues about broader applicability

In Phase 2 melanoma, favorable hazard ratios were seen regardless of:

• tumor mutational burden
• PD-1 status
• tumor inflammatory status

Hoge's interpretation was that INT may follow different biological rules from checkpoint inhibitors.

Checkpoint inhibitors release brakes on existing T cells. INT is designed to prime or expand tumor-specific T-cell populations.

That is one reason the RCC result will be particularly informative.

8. Melanoma approval could accelerate other indications

If melanoma is approved, much of the manufacturing, CMC and safety package would already be established.

Hoge suggested that if the randomized RCC or MIBC Phase 2 trials show a strong and statistically significant benefit, they could potentially support registration without automatically requiring another full Phase 3.

That could materially accelerate INT expansion.

9. Manufacturing appears much further along than many assume

Moderna says it has already treated around 3,000 INT patients globally, including roughly 1,500-2,000 in the past 18 months, across more than 40 countries.

The Marlborough manufacturing facility is highly automated and already supplying the clinical program.

Only one of seven manufacturing suites is currently needed, Moderna does not expect to need Suite 2 for launch, and capacity can be expanded substantially with roughly 12 months of lead time.

This looks very different from a CAR-T manufacturing model (a widespread concern brought up by the media in the last 2 weeks).

10. INT economics may resemble biologics, not cell therapy

The sequence is personalized for each patient, but the underlying manufacturing process and final product format are largely standardized.

Hoge therefore expects mature INT margins to resemble those of a complex biologic more than CAR-T.

That becomes increasingly important if INT expands into large indications such as lung cancer.

11. The antigen-selection algorithm could become a major moat

Moderna now has data from several thousand INT patients, versus roughly 100 patients in the original Phase 2.

That creates a potential flywheel:

More patients → more immune-response data → better antigen selection → potentially better INT → more patients/data

Moderna is also working with regulators on how future algorithm improvements could be incorporated without necessarily requiring an entirely new clinical program each time.

12. Other optionality

Retreatment: if a tumor relapses with a different mutation profile, a new INT could theoretically be created against the evolved tumor. There are no clinical data yet.

Monotherapy: NMIBC and potentially earlier-stage disease could establish INT as useful without Keytruda.

Further expansion: Moderna says it has the financial flexibility to invest in additional indications if the data justify it.

13. Financial backdrop

Moderna still targets 2028 break-even, and the current large INT program is already included in that plan.

The respiratory franchise now has five approved products and provides the financial base while INT develops.

Management is still using up to 10% top-line growth as its current framework rather than raising expectations following the melanoma result.

Bottom line

The main catalyst sequence is:

Melanoma full data → RCC → MIBC → NMIBC monotherapy → lung Phase 3s

RCC is probably the most important scientific test after melanoma. Success in a lower-TMB tumor that is biologically quite different from melanoma would materially strengthen the case that INT is a broadly applicable cancer platform.

The other major takeaway is the expected cadence: waves of INT clinical data roughly every six months.

The Phase 3 melanoma success may therefore be less of an endpoint and more of the first major validation event in a much larger question:

How broadly can INT work across different cancers?

"Since that announcement, experts and industry insiders have suggested to Fierce that the news has not only renewed hopes in the intismeran program, which hit a regulatory hurdle back in 2024, but also boosted prospects for other biopharmas exploring mRNA as a vehicle for personalized cancer treatments."

"When the full data do become available, investors will be looking to see whether intismeran could be used against other cancers and as broadly as Keytruda, said Myles Minter, Ph.D., a William Blair analyst.  

“We’ll have to see what the data look like, but if they look really good and this is a stepwise change in efficacy, this is standard-of-care shifting,” he told Fierce."

Interesting to see Vinay Prasad, the former troublemaker, oops, I meant former CBER director, write a piece on cancer vaccines, apparently prompted by the Moderna/Merck press release.

While I was not a fan of his time as CBER director, I think he is at his best as a critic. He acknowledges the melanoma result as a real and potentially important advance, but raises some fair questions, mostly because the actual numbers from the melanoma trial and the results from the other ongoing trials are not out yet.

Interestingly, he ends the piece by putting on an investor hat, saying that if he were an investor, he would bet on cancer producing more advances and more billions, and would be long some companies and short others.

It would be the greatest irony if the dude somehow ended up going long Moderna after seeing the ESMO data. Although, to be fair, I couldn’t really blame him. Lol.

Interesting picks:

Karim Mikhail, B.Pharm, MSc — Director, Center for Biologics Evaluation and Research

Karim Mikhail has been selected to serve as Director of CBER after serving as the center’s Acting Director.

Mikhail brings more than two decades of leadership experience spanning the pharmaceutical and biotechnology sectors as well as FDA. Since joining FDA, he has worked on initiatives to strengthen U.S. competitiveness, accelerate clinical development, and expand domestic biopharmaceutical manufacturing.

As CBER Director, Mikhail will lead the center responsible for regulating biological products, including vaccines, blood and blood products, and cellular and gene therapies.  He will focus on modernizing regulatory frameworks to accelerate drug development, including for rare diseases, without compromising rigor, and work to strengthen vaccine safety surveillance with a commitment to transparency and scientific precision.

Mikhail brings three decades of extensive leadership experience spanning the pharmaceutical and biotechnology sectors as well as FDA. Since joining FDA, he has worked on initiatives to accelerate clinical development, strengthen U.S. competitiveness, and expand domestic biopharmaceutical manufacturing.

As CBER Director, Mikhail will lead the center responsible for regulating biological products — including cellular and gene therapies, vaccines, and blood and blood products — ensuring American patients have access to the most innovative and safe treatments available.

Two main messages of this article from South Korea:

1. Moderna is also developing a universal cancer vaccine that would not require patient-by-patient manufacturing (mRNA-4359).

2. It is still working on its Norovirus vaccine.

A well balanced take on Moderna by a smart portfolio manager.

Very relevant post as the question of how the positive melanoma result can also apply to other cancer types is in everyone's mind.

Unrelated to the article, but just a small observation about the shorts.

When the stock rallied 100% to 170%, they cried, “Why is this stock rallying? The success of the melanoma INT was widely anticipated anyway!”

Then, when BioNTech failed and dragged Moderna’s stock down with it, they said, “See, we told you making cancer vaccines was difficult. The market is starting to realize that Moderna’s melanoma INT might just be a fluke.”

Many shorts really are clowns. The best part is that they still seem just as overconfident now, so with a little luck, we might get to watch them get roasted all over again.

JMO

Head-to-head

Cancer:
Moderna/Merck: Resected high-risk Stage IIB-IV melanoma
BioNTech/Genentech: Resected ctDNA+ high-risk Stage II / Stage III colorectal cancer

Trial:
Moderna: INTerpath-001, Phase 3, 1,137 patients
BioNTech: BNT122-01, Phase 2, ~327 patients

Experimental arm:
Moderna: Intismeran + Keytruda
BioNTech: Autogene cevumeran monotherapy after surgery and chemotherapy

Control:
Moderna: Placebo + Keytruda
BioNTech: Watchful waiting

Checkpoint inhibitor:
Moderna: Keytruda in both arms
BioNTech: None

Primary endpoint:
Moderna: RFS
BioNTech: DFS

Readout:
Moderna: Prespecified Phase 3 interim analysis. Met RFS and DMFS with statistically significant and clinically meaningful improvements. Trial continues for OS and other endpoints.

BioNTech: Not the planned final readout. An earlier prespecified interim analysis crossed the futility boundary, although the data were initially considered immature. The trial was subsequently terminated early after a later DSMB review concluded that further continuation was unlikely to change the efficacy outcome. Full results have not yet been released.

Important differences that could have contributed to the different outcomes

Tumor biology:
Moderna: Melanoma, generally highly immunogenic and responsive to immunotherapy
BioNTech: CRC, specifically described by BioNTech as an immunologically “cold” tumor with an immune-suppressive microenvironment

Checkpoint support:
Moderna: Vaccine + PD-1 blockade
BioNTech: Vaccine monotherapy, no checkpoint inhibitor

Patient selection:
Moderna: Disease-free after complete melanoma resection
BioNTech: ctDNA+ after resection, selecting patients with molecular evidence of residual disease and high recurrence risk

Previous treatment:
Moderna: No prior systemic melanoma therapy
BioNTech: Patients had already undergone surgery and standard adjuvant chemotherapy

Vaccine design/delivery:
Moderna: Up to 34 neoantigens, IM administration
BioNTech: Up to 20 neoantigens, IV RNA-LPX administration

There are skeptics, and even some cautious bulls, commenting that Moderna’s decision to raise $2B now may suggest management is unsure the stock will be higher after ESMO. I can understand the reasoning, and it's a very healthy dose of skeptism, but I personally don’t think it best explains the timing.

The Phase 3 melanoma result dramatically changed the attractiveness of Moderna’s stock to convertible-note buyers. The stock has just undergone a major re-rating, trading volume is high, and volatility has increased substantially. For convertible investors, that volatility is valuable because part of what they are buying is effectively an option on Moderna’s future share price.

That helps explain how Moderna can raise six-year capital with a 0% regular coupon. Investors are willing to accept little or no interest because the conversion feature itself has become much more valuable after the Phase 3 success.

Waiting until ESMO might allow Moderna to issue at a higher share price, but the relevant question is not simply where the stock might trade in October. The unusually high volatility, liquidity, and investor demand immediately following the Phase 3 success make the convertible particularly attractive to buyers right now, which in turn gives Moderna access to unusually favorable financing terms.

Those conditions may not persist even if the stock itself is higher after ESMO. Moderna can therefore be confident in the upcoming data and still conclude that the best financing window is today.

The structure also matters. This is not a $2B common-stock sale. Moderna is issuing convertible debt and using capped calls designed to reduce potential dilution to existing shareholders.

So I see the timing mainly as opportunistic financing. Moderna had a major positive catalyst, demand for Moderna-linked securities increased sharply, and management took advantage of that moment to secure a large amount of long-term capital on favorable terms.

This is just my interpretation and not financial advice.

Smart financing move.

There are too many to list, but the following are the catalysts I’m most looking forward to.

1. Full Phase 3 INT melanoma data and other INT related news, potentially at ESMO, Oct. 23-27

• We already know the trial for melanoma succeeded. The actual RFS and DMFS numbers will tell us how strong the result really is.
• Regulatory progress, filing timing, Priority Review, and a clearer commercialization timeline could follow.
• Further movement in NSCLC, renal, bladder, or other cancers would strengthen the case that INT is much bigger than melanoma.
• Any improvement in manufacturing speed, capacity, cost, or margins would also matter. The manufacturing difficulty could increasingly become a moat rather than an impediment.

2. Rare disease, Propionic Acidemia (PA) and MMA

• Implied by Bancel in his Fox News interview: “But I think by the end of the year, we should also become a rare genetic disease company.” (Watch "VACCINE BREAKTHROUGH: Personalized cancer treatment takes major leap" on Youtube minute 5:02)

3. November 12 Analyst Day

4. mCOMBRIAX related regulatory news

• Already approved in Europe. Japan, Canada, and Australia remain potential additional approvals. Any clearer U.S. path would be meaningful.

5. Bonus: Nasdaq-100 re-entry

• This one has barely been discussed as far as I can tell. If Moderna holds enough of its market-cap recovery through the late-November ranking period, it has a realistic shot at returning to the Nasdaq-100 in December. That would bring passive buying and potentially another momentum catalyst.

Disclaimer: This is NOT financial or investment advice.

1. “Science by press release.”

Nothing new in this criticism.

In 2021, for the COVID vaccine, Moderna did include numbers in the press release and wrote a preprint very quickly right after that, and critics still called it science by press release. After the publication of the data, the press never offered the company an apology.

Critics forget that this time there is no similar time constraint. Merck and Moderna are putting their reputation on the line here, and claiming a positive readout especially at the interim is not a joke that they can easily walk back or spin.

Just wait. They are still dotting the i’s and crossing the t’s. My speculation is that the numbers are so good that they want to make absolutely sure everything is clean before releasing them. This is easily the next major catalyst that may again surprise our shorty friends, especially if the other INT results are not already right around the corner. If my guess is right, Moderna is smart because they will be rolling out the data gradually, creating several separate waves of momentum from the same catalyst.

2. “It was largely expected and already priced in.”

Interestingly, this is being voiced mostly by people who did not own a single Moderna share and had been very hateful and negative on Moderna all along. It is funny how something becomes “obvious” only after it happens.

I actually agree that a positive result was largely expected, but by whom? It was not expected to be positive by the skeptics and haters, but by a very small group of us longs who had done our research and taken the time to separate the signal from the noise.

Interestingly, even us longs who came closest to predicting what actually transpired remain humble enough to admit that we had our occasional healthy dose of doubt during the wait.

As for priced in, feel free to tell the shorts who had to rush to cover at $170 at nearly 3 times the stock price the day before again that the event had already been priced in.

3. “The individualized neoantigen approach is unnecessary. Off-the-shelf is better.”

Sure. Moderna had nothing better to do and simply chose individualized cancer vaccines because they sounded fun.

Obviously not.

Moderna did not pursue this difficult approach for the sake of doing interesting science. It did so because a generic non-individualized approach cannot provide the same breadth of coverage across patients whose tumors carry different mutations.

Therapeutic cancer vaccines went through decades of mostly disappointing clinical results, and the individualized neoantigen approach is one of the things that finally changed that equation. Moderna was not the first to test this idea, but thanks to Bancel's obsession with AI and speed, it became the first to show clear randomized clinical efficacy with an mRNA cancer vaccine.

Cheaper non-individualized off-the-shelf vaccines may still have a role when patients share common, well-characterized antigens, but that does not make the individualized approach unnecessary.

News flash: Moderna is also working on off-the-shelf versions. Other companies, with BioNTech being one of very few obvious exceptions, can forget about dreaming that they will easily compete with Moderna even on this front, given how advanced Moderna already is in clinical development and the strength of its partnership with Merck.

4. “Manufacturing will be too difficult for commercialization.”

True for many companies. Much less convincing as an argument against Moderna, which has spent years obsessing over making individualized manufacturing commercially viable. People also seem to miss the speed angle. An individualized therapy only works commercially if you can sequence the tumor, select the neoantigens, design the medicine, manufacture a patient-specific batch and get it back to the clinic fast enough to matter. Moderna has built its manufacturing system around doing exactly that. Speed is part of the product, and the difficulty of repeatedly manufacturing thousands of different medicines for thousands of individual patients is part of the moat. If this were easy, everyone would already be doing it.

The difficulty is real, but for Moderna it has now become a moat rather than an impediment.

5. “It’s not a vaccine.”

It is a form of vaccine, but call it whatever you want. Therapeutic, individualized immunotherapy, cancer vaccine, personalized medicine. It still does not change anything. You can even call it gene therapy if you want to announce to the world that you have a double-digit IQ.

6. “I’d rather die of melanoma than get another mRNA vaccine.”

Sounds like a toddler telling their mom they would rather starve to death than eat broccoli.

People can say whatever they want while healthy. The people actually struggling with melanoma are the ones whose preferences matter here.

JMHO and this is not an investment advice.